Back

Learner’s Digest International (TM)

  • Cytokine Release Syndrome
  • Hodgkin Disease
  • Immunotherapy, Adoptive
  • Multiple Myeloma
  • Stem Cell Transplantation

Update on CAR-T Therapy: Toxicities and Management

The goal of this program is to improve management of patients with cancer with chimeric antigen receptor (CAR) T cell therapy. After hearing and assimilating this program, the clinician will be better able to: 1. Anticipate neurotoxicity and cytokine release syndrome after treatment with CAR T cell therapies. 2. Choose B cell maturation antigen-targeted therapies for treatment of multiple myeloma. 3. Identify patients with lymphoma for whom autologous stem cell transplantation is the preferred treatment. 4. Differentiate B cell maturation antigen-targeted therapies from CD19 CAR T cell therapies. 5. Select a lymphodepletion regimen for patients with relapsed or refractory Hodgkin lymphoma.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 2 credits

MOC types

ABIM — Medical KnowledgeUp to 2 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Membership pricing — $1,095 / year

This provider prices CME through membership. Individual courses may also be sold separately.

See plans on audio-digest.org

Listed by the provider

  • Enduring / On-demand
  • Credit · Up to 2 credits
  • MOC · Up to 2 points
  • Membership pricing
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Jan 8, 2027 3 months left